In a significant move that has sent waves through the healthcare sector, Exact Sciences stock has surged following the announcement that Abbott Laboratories will acquire the company in a deal valued at approximately $21 billion. The acquisition, announced on November 20, 2025, is poised to reshape the landscape of cancer diagnostics and expand Abbott's presence in the rapidly growing market.
Exact Sciences, known for its innovative cancer diagnostics, including the revolutionary Cologuard at-home colon cancer test, has been a standout performer in the molecular diagnostics sector. The acquisition by Abbott Laboratories, which will pay $105 per share, represents a significant premium on Exact Sciences' previous close, reflecting the strategic value of the deal.
The deal, which is expected to close in the second quarter of 2026, will see Abbott Laboratories acquire a company that has been at the forefront of cancer diagnostics. Exact Sciences' leadership in this field is a key factor driving the acquisition, as Abbott seeks to expand its diagnostics portfolio and capitalize on the growing demand for advanced cancer screening tools.
Analysts have highlighted the deal's potential to drive growth and innovation in the cancer diagnostics sector. The acquisition will allow Abbott to leverage Exact Sciences' expertise in molecular diagnostics, particularly in the development of non-invasive cancer screening tests. This move is seen as a strategic play to enhance Abbott's position in a market that is expected to continue growing rapidly in the coming years.
The impact on Exact Sciences stock has been immediate and dramatic. Following the announcement, Exact Sciences shares soared nearly 20% on Thursday, November 20, 2025, as investors reacted positively to the deal. The surge in stock price underscores the market's confidence in the strategic benefits of the acquisition for both companies.
The acquisition is part of a broader trend in the healthcare sector, where large conglomerates are increasingly looking to acquire innovative companies to bolster their offerings and stay competitive in a rapidly evolving market. Abbott's move to acquire Exact Sciences is a clear indication of its commitment to expanding its diagnostics capabilities and leading the way in cancer diagnostics.
The $21 billion deal marks one of the largest acquisitions in the healthcare sector this year, and it is expected to have far-reaching implications for both companies and the broader diagnostics market. As the deal moves closer to completion, investors and industry analysts will be closely watching how the integration of Exact Sciences into Abbott's portfolio plays out and what innovations may emerge from this strategic partnership.
